Correction: Progression in the LRRK2-associated Parkinson disease population (JAMA Neurology (2018) 75:3 (312-319) DOI: 10.1001/jamaneurol.2017.4019);Progression in the LRRK2-Asssociated Parkinson disease population

JAMA Neurology

Volumn 75, Issue 3, 2018, Pages 312-319

  Saunders Pullman, Rachel ^a,b   Mirelman, Anat ^c,d   Alcalay, Roy N ^e   Wang, Cuiling ^e,f   Ortega, Roberto A ^a,b   Raymond, Deborah ^a,b   Mejia Santana, Helen ^d   Orbe Reilly, Martha ^d   Johannes, Brooke A ^a,b   Thaler, Avner ^c,d   Ozelius, Laurie ^g   Orr Urtreger, Avi ^c,d   Marder, Karen S ^e,h   Giladi, Nir ^c,d   Bressman, Susan B ^a,b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e College of Physicians and Surg ^*  (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; SERINE; GBA PROTEIN, HUMAN; GLUCOSYLCERAMIDASE; LRRK2 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; ASHKENAZI JEW; CLINICAL OUTCOME; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; MOTOR DYSFUNCTION; MUTATIONAL ANALYSIS; PARKINSON DISEASE; POPULATION GENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SEX; UNIFIED PARKINSON DISEASE RATING SCALE; COGNITIVE DEFECT; COMPLICATION; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; GENETICS; MIDDLE AGED; MUTATION; SEVERITY OF ILLNESS INDEX;

ACTIVITIES OF DAILY LIVING; AGED; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLUCOSYLCERAMIDASE; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 85043491475     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2018.0748     Document Type: Erratum

References (43)

1. West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord. 2015;30(2):180-189.
2. Giladi N, Mirelman A, Thaler A, Orr-Urtreger A. A personalized approach to Parkinsons disease patients based on founder mutation analysis. Front Neurol. 2016;7(7):71.
3. Healy DG, Falchi M, OSullivan SS, et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-Associated Parkinsons disease: A case-control study. Lancet Neurol. 2008;7(7): 583-590.
4. Alcalay RN, Mirelman A, Saunders-Pullman R, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 2013;28(14):1966-1971.
5. Yahalom G, Orlev Y, Cohen OS, et al. Motor progression of Parkinsons disease with the leucine-rich repeat kinase 2 G2019S mutation. Mov Disord. 2014;29(8):1057-1060.
6. Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F. Motor phenotype of LRRK2-Associated Parkinsons disease: A Tunisian longitudinal study. Mov Disord. 2015;30(2):253-258.
7. Oosterveld LP, Allen JC Jr, Ng EY, et al. Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology. 2015;85(12):1039-1042.
8. Alcalay RN, Mejia-Santana H, Mirelman A, et al; LRRK2 Ashkenazi Jewish Consortium. Neuropsychological performance in LRRK2 G2019S carriers with Parkinsons disease. Parkinsonism Relat Disord. 2015;21(2):106-110.
9. Saunders-Pullman R, Mirelman A, Wang C, et al. Olfactory identification in LRRK2 G2019S mutation carriers: A relevant marker? Ann Clin Transl Neurol. 2014;1(9):670-678.
10. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70(24):2277-2283.
11. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007;69(16):1595-1602.
12. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinsons Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5): 427-442.
14. Schwab R, England A. Projection technique for evaluating surgery in Parkinsons disease. In: Gillingham F, Donaldson I, eds. Third Symposium on Parkinsons Disease. Edinburgh, Scotland: E&S Livingstone, 1969:152-157.
15. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
16. Diggle P, Heagerty P, Liang K-Y, Zeger Sl. Analysis of Longitudinal Data. New York, NY: Oxford University Press; 2002.
17. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
18. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinsons disease. Mov Disord. 2010;25(15):2649-2653.
19. Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the Mini Mental State Exam to the Montreal Cognitive Assessment in identifying cognitive deficits in Parkinsons disease. Mov Disord. 2008;23(2):297-299.
20. Nazem S, Siderowf AD, Duda JE, et al. Montreal Cognitive Assessment performance in patients with Parkinsons disease with "normal" global cognition according to Mini-Mental State Examination score. J AmGeriatr Soc. 2009;57(2):304-308.
21. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009; 73(21):1738-1745.
22. Cox DR. Regression models and life-Tables. J R Stat Soc B. 1972;34(2):187-220.
23. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-1615.
24. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-Treated Parkinsons disease. Mov Disord. 2000;15(3):479-484.
25. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinsons disease: A prospective study. Mov Disord. 2007;22(7):938-945.
26. Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinsons disease. Neurochem Res. 2007;32(10):1700-1708.
27. Marder K, Wang Y, Alcalay RN, et al; LRRK2 Ashkenazi Jewish Consortium. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology. 2015;85(1):89-95.
28. Wang C, Cai Y, Zheng Z, et al; Chinese Parkinson Study Group (CPSG). Penetrance of LRRK2 G2385R and R1628P is modified by common PD-Associated genetic variants. Parkinsonism Relat Disord. 2012;18(8):958-963.
29. Marras C, Alcalay RN, Caspell-Garcia C, et al; LRRK2 Cohort Consortium. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinsons disease. Mov Disord. 2016;31(8):1192-1202.
30. Simón-Sánchez J, Martí-Massó JF, Sánchez-Mut JV, et al. Parkinsons disease due to the R1441G mutation in Dardarin: A founder effect in the Basques. Mov Disord. 2006;21(11):1954-1959.
31. von Coelln R, Shulman LM. Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr Opin Neurol. 2016;29 (6):727-734.
32. Fereshtehnejad S-M, Romenets SR, Anang JB, Latreille V, Gagnon J-F, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-873.
33. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol. 2011;69(1):193-197.
34. Thaler A, Helmich RC, Or-Borichev A, et al; LRRK2 Ashkenazi Jewish Consortium. Intact working memory in non-manifesting LRRK2 carriers-An fMRI study. Eur J Neurosci. 2016;43(1): 106-112.
35. Halliday GM, McCann H. The progression of pathology in Parkinsons disease. Ann N Y Acad Sci. 2010;1184(1):188-195.
36. Compta Y, Parkkinen L, OSullivan SS, et al. Lewy-And Alzheimer-Type pathologies in Parkinsons disease dementia: which is more important? Brain. 2011;134(pt 5):1493-1505.
37. Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72(1):100-105.
38. Gaig C, Martí MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E. G2019S LRRK2 mutation causing Parkinsons disease without Lewy bodies. J Neurol Neurosurg Psychiatry. 2007;78(6):626-628.
39. Saunders-Pullman R, Alcalay RN, Mirelman A, et al; AJ LRRK2 Consortium. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Mov Disord. 2015; 30(13):1834-1839.
40. Pont-Sunyer C, Iranzo A, Gaig C, et al. Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One. 2015;10(7): e0132368.
41. Trinh J, Amouri R, Duda JE, et al. Comparative study of Parkinsons disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol Aging. 2014;35(5):1125-1131.
42. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: A systematic review. Arch Neurol. 2002;59(11):1724-1728.
43. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: A population-based study. Neurology. 2005;65(9):1436-1441.